ReviewEuropean respiratory review : an official journal of the European Respiratory Society2013
The impact of emphysema in pulmonary fibrosis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- The effect of CALIPER-derived parameters for idiopathic pulmonary fibrosis in predicting prognosis, progression, and mortality: a systematic review.European radiology · 2023Pooled it
- Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review.Lung · 2017Pooled it
- Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone.Therapeutic advances in respiratory diseasePooled it
- An increased risk of lung cancer in combined pulmonary fibrosis and emphysema patients with usual interstitial pneumonia compared with patients with idiopathic pulmonary fibrosis alone: a systematic review and meta-analysis.Therapeutic advances in respiratory diseasePooled it
- The Presence of Emphysema in Patients with Idiopathic Pulmonary Fibrosis and Lung Cancer: Impact on Tumor Features, Acute Exacerbation, and Survival.Journal of clinical medicine · 2025Article
- Article
- Research progress of SIRTs activator resveratrol and its derivatives in autoimmune diseases.Frontiers in immunology · 2024Review
- Identifying health risk determinants and molecular targets in patients with idiopathic pulmonary fibrosis via combined differential and weighted gene co-expression analysis.Frontiers in genetics · 2024Article
- Transitional cell states sculpt tissue topology during lung regeneration.Cell stem cell · 2023Article
- Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition.Biomedicines · 2023Review
- The Impact of Lung Cancer in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE).Journal of clinical medicine · 2023Article
- Serum Krebs von den Lungen-6: promising biomarker to differentiate CPFE from IPF.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Article
- Immunotherapy for combined pulmonary fibrosis and emphysema with advanced lung cancer: two case reports and a concise review.Translational cancer research · 2022Article
- Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population.BMC pulmonary medicine · 2022Article
- Interstitial lung abnormalities and interstitial lung diseases associated with cigarette smoking in a rural cohort undergoing surgical resection.BMC pulmonary medicine · 2022Article
- Chronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease.Tuberculosis and respiratory diseases · 2022Review
- Quantitative determination of pulmonary emphysema in follow-up LD-CTs of patients with COVID-19 infection.PloS one · 2022Article
- Article
- Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management.Respiratory research · 2021Review
- Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome.ERJ open research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several groups have described a syndrome in which idiopathic pulmonary fibrosis (IPF) coexists with pulmonary emphysema. This comes as no surprise since both diseases are associated with a history of exposure to cigarette smoke. The syndrome of combined pulmonary fibrosis and emphysema (CPFE) is characterised by upper lobe emphysema and lower lobe fibrosis. Physiological testing of these patients reveals preserved lung volume indices contrasted by markedly impaired diffusion capacity. The incidence of CPFE remains unknown but several case series suggest that this subgroup may comprise up to 35% of patients with IPF. CPFE is a strong determinant of associated pulmonary hypertension (PH). In addition, CPFE has major effects on measures of physiological function, exercise capacity and prognosis, and may affect the results of pulmonary fibrosis trials. Further studies are needed to ascertain the aetiology, morbidity, mortality and management of the CPFE syndrome, with or without PH, and to evaluate novel therapeutic options in CPFE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.